Advanced search
Publication Cover
OncoImmunology Volume 9, 2020 - Issue 1
Submit an article Journal homepage
11,037
Views
147
CrossRef citations to date
0
Altmetric
Review

Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology

Isaure Vanmeerbeeka Cell Death Research & Therapy (CDRT) unit, Department of Cellular & Molecular Medicine, KU Leuven, Leuven, Belgium
,
Jenny Sprootena Cell Death Research & Therapy (CDRT) unit, Department of Cellular & Molecular Medicine, KU Leuven, Leuven, Belgium
,
Dirk De Ruysscherb Maastricht University Medical Center, Department of Radiation Oncology (MAASTRO Clinic), GROW-School for Oncology and Developmental Biology, Maastricht, Netherlands
,
Sabine Tejparc Department of Oncology, KU Leuven, Leuven, Belgium;d UZ Leuven, Leuven, Belgium
,
Peter Vandenberghee Department of Haematology, UZ Leuven, and Department of Human Genetics, KU Leuven, Leuven, Belgium
,
Jitka Fucikovaf Sotio, Prague, Czech Republic;g Department of Immunology, 2 Faculty of Medicine and University Hospital Motol, Charles University, Prague, Czech Republic
,
Radek Spisekf Sotio, Prague, Czech Republic;g Department of Immunology, 2 Faculty of Medicine and University Hospital Motol, Charles University, Prague, Czech Republic
,
Laurence Zitvogelh Gustave Roussy Comprehensive Cancer Institute, Villejuif, France;i INSERM, U1015, Villejuif, France;j Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, France;k Université Paris Sud/Paris XI, Le Kremlin-Bicêtre, FranceORCID Iconhttps://orcid.org/0000-0003-1596-0998
ORCID Icon,
Guido Kroemerl Equipe labellisée par la Ligue contre le cancer, Centre de Recherche des Cordeliers, Université de Paris, Sorbonne Université, INSERM U1138, Paris, France;m Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France;n Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France;o Suzhou Institute for Systems Medicine, Chinese Academy of Medical Sciences, Suzhou, China;p Department of Women’s and Children’s Health, Karolinska University Hospital, Stockholm, SwedenORCID Iconhttps://orcid.org/0000-0002-9334-4405
ORCID Icon,
Lorenzo Galluzziq Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA;r Sandra and Edward Meyer Cancer Center, New York, NY, USA;s Caryl and Israel Englander Institute for Precision Medicine, New York, NY, USA;t Department of Dermatology, Yale School of Medicine, New Haven, CT, USA;u Université de Paris, Paris, FranceCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-2257-8500
ORCID Icon &
Abhishek D. Garga Cell Death Research & Therapy (CDRT) unit, Department of Cellular & Molecular Medicine, KU Leuven, Leuven, BelgiumCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-9976-9922
ORCID Icon show all
Article: 1703449 | Received 28 Oct 2019, Accepted 01 Nov 2019, Published online: 09 Jan 2020

Citations (147)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (15)

Jenny Sprooten, Raquel S. Laureano, Isaure Vanmeerbeek, Jannes Govaerts, Stefan Naulaerts, Daniel M. Borras, Lisa Kinget, Jitka Fucíková, Radek Špíšek, Lenka Palová Jelínková, Oliver Kepp, Guido Kroemer, Dmitri V. Krysko, An Coosemans, Rianne D.W. Vaes, Dirk De Ruysscher, Steven De Vleeschouwer, Els Wauters, Evelien Smits, Sabine Tejpar, Benoit Beuselinck, Sigrid Hatse, Hans Wildiers, Paul M. Clement, Peter Vandenabeele, Laurence Zitvogel & Abhishek D. Garg. (2023) Trial watch: chemotherapy-induced immunogenic cell death in oncology. OncoImmunology 12:1.
Read now
Ines Marin, Manuel Serrano & Federico Pietrocola. (2023) Cellular senescence enhances adaptive anticancer immunosurveillance. OncoImmunology 12:1.
Read now
Raquel S Laureano, Jenny Sprooten, Isaure Vanmeerbeerk, Daniel M Borras, Jannes Govaerts, Stefan Naulaerts, Zwi N Berneman, Benoit Beuselinck, Kalijn F Bol, Jannie Borst, an Coosemans, Angeliki Datsi, Jitka Fučíková, Lisa Kinget, Bart Neyns, Gerty Schreibelt, Evelien Smits, Rüdiger V Sorg, Radek Spisek, Kris Thielemans, Sandra Tuyaerts, Steven De Vleeschouwer, I Jolanda M de Vries, Yanling Xiao & Abhishek D Garg. (2022) Trial watch: Dendritic cell (DC)-based immunotherapy for cancer. OncoImmunology 11:1.
Read now
Peng Liu, Jianzhou Chen, Liwei Zhao, Antoine Hollebecque, Oliver Kepp, Laurence Zitvogel & Guido Kroemer. (2022) PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer. OncoImmunology 11:1.
Read now
G. Kofla, C. Radecke, M. Frentsch, W. Walther, S. Stintzing, H. Riess, L. Bullinger & I-K. Na. (2022) Conventional amphotericin B elicits markers of immunogenic cell death on leukemic blasts, mediates immunostimulatory effects on phagocytic cells, and synergizes with PD-L1 blockade. OncoImmunology 11:1.
Read now
Julie Le Naour, Zsofia Sztupinszki, Vincent Carbonnier, Odile Casiraghi, Virginie Marty, Lorenzo Galluzzi, Zoltan Szallasi, Guido Kroemer & Erika Vacchelli. (2022) A loss-of-function polymorphism in ATG16L1 compromises therapeutic outcome in head and neck carcinoma patients. OncoImmunology 11:1.
Read now
Dule Hao, Zheng Zhang & Yuanhui Ji. (2022) Responsive polymeric drug delivery systems for combination anticancer therapy: experimental design and computational insights. International Journal of Polymeric Materials and Polymeric Biomaterials 71:16, pages 1221-1239.
Read now
Man Kyu Shim, Su Kyung Song, Seong Ik Jeon, Kwang Yeon Hwang & Kwangmeyung Kim. (2022) Nano-sized drug delivery systems to potentiate the immune checkpoint blockade therapy. Expert Opinion on Drug Delivery 19:6, pages 641-652.
Read now
Debora Basile, Francesca Simionato, Lorenzo Calvetti, Alessandro Cappetta, Annalisa Pesavento, Marta Mongillo, Giandomenico Roviello, Gerardo Rosati, Gemma Rossi & Giuseppe Aprile. (2021) Comparing immunotherapies to other frequently used treatments of gastric cancer. Expert Review of Clinical Pharmacology 14:10, pages 1221-1232.
Read now
Kamal S Saini, Kevin Punie, Chris Twelves, Stefanella Bortini, Evandro de Azambuja, Steven Anderson, Carmen Criscitiello, Ahmad Awada & Sherene Loi. (2021) Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics. Expert Opinion on Biological Therapy 21:7, pages 945-962.
Read now
Juliette Humeau, Julie Le Naour, Lorenzo Galluzzi, Guido Kroemer & Jonathan G. Pol. (2021) Trial watch: intratumoral immunotherapy. OncoImmunology 10:1.
Read now
Jialin Qu, Li Wang, Man Jiang, Deze Zhao, Yuyang Wang, Feng Zhang, Jing Li & Xiaochun Zhang. (2020) A Review About Pembrolizumab in First-Line Treatment of Advanced NSCLC: Focus on KEYNOTE Studies. Cancer Management and Research 12, pages 6493-6509.
Read now
Giorgio Frega, Qi Wu, Julie Le Naour, Erika Vacchelli, Lorenzo Galluzzi, Guido Kroemer & Oliver Kepp. (2020) Trial Watch: experimental TLR7/TLR8 agonists for oncological indications. OncoImmunology 9:1.
Read now
Julie Le Naour, Lorenzo Galluzzi, Laurence Zitvogel, Guido Kroemer & Erika Vacchelli. (2020) Trial watch: IDO inhibitors in cancer therapy. OncoImmunology 9:1.
Read now
Jonathan G. Pol, Julie Le Naour & Guido Kroemer. (2020) FLT3LG - a biomarker reflecting clinical responses to the immunogenic cell death inducer oxaliplatin. OncoImmunology 9:1.
Read now

Articles from other publishers (132)

Xier Pan, Shuting Ni & Kaili Hu. (2024) Nanomedicines for reversing immunosuppressive microenvironment of hepatocellular carcinoma. Biomaterials 306, pages 122481.
Crossref
Ping Sun, Li Huang, Zimu Li, Yao Yang, Shiman Lu, Nansha Gao, Hongzhong Chen, Xiaowei Zeng & Zhongjian Xie. (2024) Charge-reversal biodegradable nanoplatform with ferroptosis and ICD induction for tumor synergistic treatment. Chemical Engineering Journal 483, pages 149234.
Crossref
Shixiang Wang, Chen-Yi Wu, Ming-Ming He, Jia-Xin Yong, Yan-Xing Chen, Li-Mei Qian, Jin-Ling Zhang, Zhao-Lei Zeng, Rui-Hua Xu, Feng Wang & Qi Zhao. (2024) Machine learning-based extrachromosomal DNA identification in large-scale cohorts reveals its clinical implications in cancer. Nature Communications 15:1.
Crossref
Yurika Nakayama, Takayuki Ando, Naoki Takahashi, Kenichiro Tsukada, Hiroaki Takagi, Yuno Goto, Atsuko Nakaya, Naokatsu Nakada, Hiroki Yoshita, Iori Motoo, Akira Ueda, Yuko Ueda, Miho Sakumura, Shinya Kajiura, Kohei Ogawa, Ayumu Hosokawa & Ichiro Yasuda. (2024) The Efficacy and Safety of Nivolumab Plus mFOLFOX6 in Gastric Cancer with Severe Peritoneal Metastasis. Journal of Clinical Medicine 13:3, pages 834.
Crossref
Francesca De Felice, Carlo G. Cattaneo, Gianmario E. Poto, Carmine Antropoli, Antonio Brillantino, Ludovico Carbone, Oronzo Brunetti, Raffaele De Luca, Isacco Desideri, Lorena Incorvaia, Roberta La Mendola, Federica Marmorino, Dario Parini, Maria G. Rodriquenz, Viola Salvestrini, Federica Sebastiani, Karol Polom & Luigi Marano. (2024) Mapping the landscape of immunonutrition and cancer research: a comprehensive bibliometric analysis on behalf of NutriOnc Research Group. International Journal of Surgery 110:1, pages 395-405.
Crossref
Qian Hu, Shukai Wang, Ruiyang Cheng, Yuqi Liu, Zihao Chang, Ya Huang, Yinxin Chen, Xiaowei Luo, Lipeng Zhou, Baojin Wang, Ye Gao, Hongjiao Chen, Runping Liu & Lanzhen Zhang. (2024) Tannins in Phyllanthus emblica L. improves cisplatin efficacy in lung cancer cells by boosting endoplasmic reticulum stress to trigger immunogenic cell death. Phytomedicine 123, pages 155219.
Crossref
Nayeon Shim, Hanhee Cho, Seong Ik Jeon & Kwangmeyung Kim. (2023) Recent developments in chemodrug-loaded nanomedicines and their application in combination cancer immunotherapy. Journal of Pharmaceutical Investigation 54:1, pages 13-36.
Crossref
Guibin Pang, Siqi Wei, Jian Zhao & Fu-Jun Wang. (2023) Improving nanochemoimmunotherapy efficacy by boosting “eat-me” signaling and downregulating “don't-eat-me” signaling with Ganoderma lucidum polysaccharide-based drug delivery . Journal of Materials Chemistry B 11:48, pages 11562-11577.
Crossref
Xiaojun Huang, Qinghuan Ren, Leixiang Yang, Di Cui, Chenyang Ma, Yueliang Zheng & Junjie Wu. (2023) Immunogenic chemotherapy: great potential for improving response rates. Frontiers in Oncology 13.
Crossref
Dalila Carbone, Carmela Gallo, Genoveffa Nuzzo, Giusi Barra, Mario Dell’Isola, Mario Affuso, Olimpia Follero, Federica Albiani, Clementina Sansone, Emiliano Manzo, Giuliana d’Ippolito & Angelo Fontana. (2023) Marine natural product lepadin A as a novel inducer of immunogenic cell death via CD91-dependent pathway. Natural Products and Bioprospecting 13:1.
Crossref
Kenny Misael Calvillo-Rodríguez, Helen Yarimet Lorenzo-Anota, Cristina Rodríguez-Padilla, Ana Carolina Martínez-Torres & Daniel Scott-Algara. (2023) Immunotherapies inducing immunogenic cell death in cancer: insight of the innate immune system. Frontiers in Immunology 14.
Crossref
Yechan Choi & Keehoon Jung. (2023) Normalization of the tumor microenvironment by harnessing vascular and immune modulation to achieve enhanced cancer therapy. Experimental & Molecular Medicine 55:11, pages 2308-2319.
Crossref
Yesim Eralp & Utku Ates. (2023) Clinical Applications of Combined Immunotherapy Approaches in Gastrointestinal Cancer: A Case-Based Review. Vaccines 11:10, pages 1545.
Crossref
Yang Qin, Haitao Zhang, Yunxian Li, Ting Xie, Shuang Yan, Jiaqi Wang, Jun Qu, Feijun Ouyang, Shaoyang Lv, Zifen Guo, Hua Wei & Cui‐Yun Yu. (2023) Promotion of ICD via Nanotechnology. Macromolecular Bioscience 23:9.
Crossref
Zhishan Xu, Mengke Xu, Xueya Wu, Sheng Guo, Zhongwei Tian, Di Zhu, Jixuan Yang, Jiyun Fu, Xi Li, Guozhen Song, Zhe Liu & Xiangfeng Song. (2023) A Half‐Sandwich Ruthenium(II) (N^N) Complex: Inducing Immunogenic Melanoma Cell Death in Vitro and in Vivo. ChemMedChem 18:16.
Crossref
Jing Xu, Caixia Liu, Xiaonan WuJie Ma. (2023) Current immune therapeutic strategies in advanced or metastatic non-small cell lung cancer. Chinese Medical Journal 136:15, pages 1765-1782.
Crossref
Benjamin G. Vincent, Danielle M. File, Karen P. McKinnon, Dominic T. Moore, Jeffrey A. Frelinger, Edward J. Collins, Joseph G. Ibrahim, Lisa Bixby, Shannon Reisdorf, Sonia J. Laurie, Yara A. Park, Carey K. Anders, Frances A. Collichio, Hyman B. Muss, Lisa A. Carey, Hendrik W. van Deventer, E. Claire Dees & Jonathan S. Serody. (2023) Efficacy of a Dual-Epitope Dendritic Cell Vaccine as Part of Combined Immunotherapy for HER2-Expressing Breast Tumors. The Journal of Immunology 211:2, pages 219-228.
Crossref
Xiaohui Yang, Junling Yang, Xiaoxia Gu, Yuhua Tao, Hongjuan Ji, Xian Miao, Shuijie Shen & Haiyang Zang. (2022) (−)-Guaiol triggers immunogenic cell death and inhibits tumor growth in non-small cell lung cancer. Molecular and Cellular Biochemistry 478:7, pages 1611-1620.
Crossref
Pengping Li, Wei Wang, Shaowen Wang, Guodong Cao, Tonghe Pan, Yuqing Huang, Hong Wan, Weijun Zhang, Yate Huang, Haigang Jin & Zhenyu Wang. (2023) PTPRC promoted CD8+ T cell mediated tumor immunity and drug sensitivity in breast cancer: based on pan-cancer analysis and artificial intelligence modeling of immunogenic cell death-based drug sensitivity stratification. Frontiers in Immunology 14.
Crossref
Rong-Rong Zheng, Lin-Ping Zhao, Chu-Yu Huang, Hong Cheng, Ni Yang, Zu-Xiao Chen, Hua Cai, Wei Zhang, Ren-Jiang Kong & Shi-Ying Li. (2023) Paraptosis Inducer to Effectively Trigger Immunogenic Cell Death for Metastatic Tumor Immunotherapy with IDO Inhibition. ACS Nano 17:11, pages 9972-9986.
Crossref
Zhen Zhang, Jiaqian Huang, Yuhong Xu & Huiyan Luo. (2023) Chemoimmunotherapy for esophageal squamous cell carcinoma—Summary and discussion of recent clinical trials. MedComm – Future Medicine 2:3.
Crossref
Ioannis M. Koukourakis, Marios Papadimitriou, Dimitra Desse, Anna Zygogianni & Christos Papadimitriou. (2023) Anti-Tumor Immunity and Preoperative Radiovaccination: Emerging New Concepts in the Treatment of Breast Cancer. International Journal of Molecular Sciences 24:11, pages 9310.
Crossref
Camil Ciprian Mireștean, Roxana Irina Iancu & Dragoș Teodor Iancu. (2023) Radiotherapy and Immunotherapy—A Future Partnership towards a New Standard. Applied Sciences 13:9, pages 5643.
Crossref
Qian Chen, Chunyan Li & Qiangbin Wang. (2023) Multifunctional Nano‐Biomaterials for Cancer Therapy via Inducing Enhanced Immunogenic Cell Death. Small Methods 7:5.
Crossref
Tian Tian, Bei Zhao, Huizhen Wei, Mengru Sun, Zhaoshuai Gao, Min Lv, Haozhi Lei, Zhilei Ge & Guangbo Ge. (2023) Programing Immunogenic Cell Death in Breast Tumors with Designer DNA Frameworks. JACS Au 3:4, pages 1241-1249.
Crossref
Jiaqi Zhai, Xi Gu, Yang Liu, Yueting Hu, Yi Jiang & Zhenyong Zhang. (2023) Chemotherapeutic and targeted drugs-induced immunogenic cell death in cancer models and antitumor therapy: An update review. Frontiers in Pharmacology 14.
Crossref
Suna Zhou & Haihua Yang. (2023) Immunotherapy resistance in non-small-cell lung cancer: From mechanism to clinical strategies. Frontiers in Immunology 14.
Crossref
Ning Han, Zi-Yi Yang, Zhong-Xiong Xie, Hua-Zhen Xu, Ting-Ting Yu, Qi-Rui Li, Liu-Gen Li, Xing-Chun Peng, Xiao-Xin Yang, Jun Hu, Xiang Xu, Xiao Chen, Mei-Fang Wang & Tong-Fei Li. (2023) Dihydroartemisinin elicits immunogenic death through ferroptosis-triggered ER stress and DNA damage for lung cancer immunotherapy. Phytomedicine 112, pages 154682.
Crossref
Xuejun Gan, Xiaohuan Tang & Ziyu Li. (2023) Identification of Immunogenic Cell-Death-Related Subtypes and Development of a Prognostic Signature in Gastric Cancer. Biomolecules 13:3, pages 528.
Crossref
Wenpan Li, Yanhao Jiang & Jianqin Lu. (2023) Nanotechnology-enabled immunogenic cell death for improved cancer immunotherapy. International Journal of Pharmaceutics 634, pages 122655.
Crossref
Giuseppina Catania, Giulia Rodella, Kevin Vanvarenberg, Véronique Préat & Alessio Malfanti. (2023) Combination of hyaluronic acid conjugates with immunogenic cell death inducer and CpG for glioblastoma local chemo-immunotherapy elicits an immune response and induces long-term survival. Biomaterials 294, pages 122006.
Crossref
Yuan-Ling Tang, Dan-Dan Li, Jia-Yu Duan, Lei-Ming Sheng & Xin Wang. (2023) Resistance to targeted therapy in metastatic colorectal cancer: Current status and new developments. World Journal of Gastroenterology 29:6, pages 926-948.
Crossref
Lalitha Palanivelu, Ching-Hsuan Liu & Liang-Tzung Lin. (2023) Immunogenic cell death: The cornerstone of oncolytic viro-immunotherapy. Frontiers in Immunology 13.
Crossref
Jacinth Wing-Sum Cheu, Derek Lee, Qidong Li, Chi Ching Goh, Macus Hao-Ran Bao, Vincent Wai-Hin Yuen, Misty Shuo Zhang, Chunxue Yang, Cerise Yuen-Ki Chan, Aki Pui-Wah Tse, Grace Fu-Wan Sit, Cindy Xinqi Liu, Irene Oi-Lin Ng, Chun-Ming Wong & Carmen Chak-Lui Wong. (2023) Ferroptosis Suppressor Protein 1 Inhibition Promotes Tumor Ferroptosis and Anti-tumor Immune Responses in Liver Cancer. Cellular and Molecular Gastroenterology and Hepatology 16:1, pages 133-159.
Crossref
Idoko Salifu, Navneet Singh, Maria Berraondo, Jordi Remon, Stephanie Salifu, Eric Severson, Angela Quintana, Sandra Peiró, Shakti Ramkissoon, Laura Vidal, Isagani Chico & Kamal S. Saini. (2023) Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in advanced non-small cell lung cancer. Cancer Treatment and Research Communications 36, pages 100713.
Crossref
Honey Pavithran, Angelina Job Kolady & Ranjith Kumavath. 2023. Computational Methods in Drug Discovery and Repurposing for Cancer Therapy. Computational Methods in Drug Discovery and Repurposing for Cancer Therapy 237 258 .
Juliette Humeau, Julie Le Naour, Guido Kroemer & Jonathan G. Pol. 2023.
Mengshi Jiang, Bing Qin, Xiang Li, Yu Liu, Guannan Guan & Jian You. (2022) New advances in pharmaceutical strategies for sensitizing anti‐PD ‐1 immunotherapy and clinical research . WIREs Nanomedicine and Nanobiotechnology 15:1.
Crossref
Isaure Vanmeerbeek, Jannes Govaerts, Raquel S. Laureano, Jenny Sprooten, Stefan Naulaerts, Daniel M. Borras, Damya Laoui, Massimiliano Mazzone, Jo A. Van Ginderachter & Abhishek D. Garg. (2022) The Interface of Tumour-Associated Macrophages with Dying Cancer Cells in Immuno-Oncology. Cells 11:23, pages 3890.
Crossref
Laura Hartmann, Wolfram Osen, Oliver L. Eichmüller, Theresa Kordaß, Jennifer Furkel, Elke Dickes, Carissa Reid, Jürgen Debus, Stephan Brons, Amir Abdollahi, Mahmoud Moustafa, Stefan Rieken & Stefan B. Eichmüller. (2022) Carbon ion irradiation plus CTLA4 blockade elicits therapeutic immune responses in a murine tumor model. Cancer Letters 550, pages 215928.
Crossref
Aparna Kalyan, Harshit Khosla & Richard D. Kim. (2022) Immunotherapy in Biliary Tract Cancers: Where Are We?. Current Oncology Reports 24:12, pages 1821-1828.
Crossref
Kellsye P. Fabian, Joshua T. Kowalczyk, Sandy T. Reynolds & James W. Hodge. (2022) Dying of Stress: Chemotherapy, Radiotherapy, and Small-Molecule Inhibitors in Immunogenic Cell Death and Immunogenic Modulation. Cells 11:23, pages 3826.
Crossref
Wei-Bang Yu, Yu-Chi Chen, Can-Yu Huang, Zi-Han Ye, Wei Shi, Hong Zhu, Jia-Jie Shi, Jun Chen & Jin-Jian Lu. (2022) CD47 blockade improves the therapeutic effect of osimertinib in non-small cell lung cancer. Frontiers of Medicine.
Crossref
Katharine Gurgel Dias Florêncio, Evelline Araújo Edson, Keilla Santana da Silva Fernandes, João Paulo Mesquita Luiz, Francisco das Chagas Lima Pinto, Otília Deusdênia Loiola Pessoa, Fernando de Queiroz Cunha, João Agostinho Machado-Neto & Diego Veras Wilke. (2022) Chromomycin A5 induces bona fide immunogenic cell death in melanoma. Frontiers in Immunology 13.
Crossref
Chang-Ting Lin, Po-Jung Su, Shih-Yu Huang, Chia-Che Wu, Hung-Jen Wang, Yuan-Tso Cheng, Hao-Lun Luo, Chien-Hsu Chen, Ting-Ting Liu, Chun-Chieh Huang & Yu-Li Su. (2022) First-line Immune Checkpoint Inhibitor Versus Immune Checkpoint Inhibitor With Chemotherapy for Cisplatin-ineligible Metastatic Urothelial Carcinoma: Evidence From a Real-world, Multicenter Analysis. Journal of Immunotherapy 45:9, pages 407-414.
Crossref
Spyridon Giannopoulos, Cansu Cimen Bozkus, Eleni Zografos, Aikaterini Athanasiou, Ann Marie Bongiovanni, Georgios Doulaveris, Chris N. Bakoyiannis, Georgios E. Theodoropoulos, Georgios C. Zografos, Steven S. Witkin & Theofano Orfanelli. (2022) Targeting Both Autophagy and Immunotherapy in Breast Cancer Treatment. Metabolites 12:10, pages 966.
Crossref
Kumara Swamy. (2022) Vascular normalization and immunotherapy: Spawning a virtuous cycle. Frontiers in Oncology 12.
Crossref
Jun Yuan, Jiarui Li, Ce Gao, Chun Jiang, Ze Xiang & Jian Wu. (2022) Immunotherapies catering to the unmet medical need of cold colorectal cancer. Frontiers in Immunology 13.
Crossref
Songshan Feng, Xisong Liang, Jing Li, Zeyu Wang, Hao Zhang, Ziyu Dai, Peng Luo, Zaoqu Liu, Jian Zhang, Xiaoxiong Xiao & Quan Cheng. (2022) Immunogenic cell death related risk model to delineate ferroptosis pathway and predict immunotherapy response of patients with GBM. Frontiers in Immunology 13.
Crossref
Jeongrae Kim, Yongwhan Choi, Dong-Hwee Kim, Hong Yeol Yoon & Kwangmeyung Kim. (2022) Injectable Hydrogel-Based Combination Cancer Immunotherapy for Overcoming Localized Therapeutic Efficacy. Pharmaceutics 14:9, pages 1908.
Crossref
Emily R. Webb, Julia Moreno-Vicente, Alistair Easton, Silvia Lanati, Martin Taylor, Sonya James, Emily L. Williams, Vikki English, Chris Penfold, Stephen A. Beers & Juliet C. Gray. (2022) Cyclophosphamide depletes tumor infiltrating T regulatory cells and combined with anti-PD-1 therapy improves survival in murine neuroblastoma. iScience 25:9, pages 104995.
Crossref
Pengkai Wu, Haitian Zhang, Meiling Sun, Shuai Mao, Qifeng He, Yuze Shi, Yexuan Deng, Zhongjun Dong, Qingxiang Xu, Chen Zhao, Wenjie Zhang & Beicheng Sun. (2022) Manipulating Offense and Defense Signaling to Fight Cold Tumors with Carrier‐Free Nanoassembly of Fluorinated Prodrug and siRNA. Advanced Materials 34:38.
Crossref
Xinye Qian, Wang Hu & Jun Yan. (2022) Nano-Chemotherapy synergize with immune checkpoint inhibitor- A better option?. Frontiers in Immunology 13.
Crossref
Raj G. Vaghjiani & Joseph J. Skitzki. (2022) Tertiary Lymphoid Structures as Mediators of Immunotherapy Response. Cancers 14:15, pages 3748.
Crossref
Qixiong Zhang, Shanshan Li, Jiandong Ren, Xia He, Houkui Shi, Fuzhong Zhang, Hui Li & Rongsheng Tong. (2022) ROS-triggered nanoinducer based on dermatan sulfate enhances immunogenic cell death in melanoma. Journal of Controlled Release 348, pages 22-33.
Crossref
Mosar Corrêa Rodrigues, José Athayde Vasconcelos Morais, Rayane Ganassin, Giulia Rosa Tavares Oliveira, Fabiana Chagas Costa, Amanda Alencar Cabral Morais, Ariane Pandolfo Silveira, Victor Carlos Mello Silva, João Paulo Figueiró Longo & Luis Alexandre Muehlmann. (2022) An Overview on Immunogenic Cell Death in Cancer Biology and Therapy. Pharmaceutics 14:8, pages 1564.
Crossref
Lei Zhu, Hui Mao & Lily Yang. (2022) Advanced iron oxide nanotheranostics for multimodal and precision treatment of pancreatic ductal adenocarcinoma. WIREs Nanomedicine and Nanobiotechnology 14:4.
Crossref
Xiaolin Xiong, Ke-Bin Huang, Yuan Wang, Bei Cao, Yunli Luo, Huowen Chen, Yan Yang, Yan Long, Moyi Liu, Albert S. C. Chan, Hong Liang & Taotao Zou. (2022) Target Profiling of an Iridium(III)-Based Immunogenic Cell Death Inducer Unveils the Engagement of Unfolded Protein Response Regulator BiP. Journal of the American Chemical Society 144:23, pages 10407-10416.
Crossref
Marine Jary, Wen‐Wei Liu, Dongyao Yan, Isaac Bai, Andrea Muranyi, Elise Colle, Isabelle Brocheriou, Anthony Turpin, Nina Radosevic‐Robin, Pierre Bourgoin, Frédérique Penault‐Llorca, Romain Cohen, Dewi Vernerey, Thierry André, Christophe Borg, Kandavel Shanmugam & Magali Svrcek. (2022) Immune microenvironment in patients with mismatch‐repair‐proficient oligometastatic colorectal cancer exposed to chemotherapy: the randomized MIROX GERCOR cohort study. Molecular Oncology 16:11, pages 2260-2273.
Crossref
Jitka Fucikova, Lenka Palova-Jelinkova, Vanessa Klapp, Peter Holicek, Tereza Lanickova, Lenka Kasikova, Jana Drozenova, David Cibula, Beatriz Álvarez-Abril, Elena García-Martínez, Radek Spisek & Lorenzo Galluzzi. (2022) Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents. Trends in Cancer 8:5, pages 426-444.
Crossref
Laura Brennan, Jurriaan Brouwer-Visser, Eveline Nüesch, Maria Karpova, Astrid Heller, Fabien Gaire, Meike Schneider, Bruno Gomes & Konstanty Korski. (2022) T-Cell Heterogeneity in Baseline Tumor Samples: Implications for Early Clinical Trial Design and Analysis. Frontiers in Immunology 13.
Crossref
André E. Nel, Kuo-Ching Mei, Yu-Pei Liao & Xiangsheng Liu. (2022) Multifunctional Lipid Bilayer Nanocarriers for Cancer Immunotherapy in Heterogeneous Tumor Microenvironments, Combining Immunogenic Cell Death Stimuli with Immune Modulatory Drugs. ACS Nano 16:4, pages 5184-5232.
Crossref
Cathrin L. C. Gudd & Lucia A. Possamai. (2022) The Role of Myeloid Cells in Hepatotoxicity Related to Cancer Immunotherapy. Cancers 14:8, pages 1913.
Crossref
Fotis Nikolos, Kazukuni Hayashi, Xen Ping Hoi, Mark Ellie Alonzo, Qianxing Mo, Armine Kasabyan, Hideki Furuya, Jane Trepel, Dolores Di Vizio, Jlenia Guarnerio, Dan Theodorescu, Charles Rosser, Andrea Apolo, Matthew Galsky & Keith Syson Chan. (2022) Cell death-induced immunogenicity enhances chemoimmunotherapeutic response by converting immune-excluded into T-cell inflamed bladder tumors. Nature Communications 13:1.
Crossref
Jiehan Li, Guang Luo, Chuchu Zhang, Shuaiyu Long, Leiming Guo, Ge Yang, Feng Wang, Lingling Zhang, Liyang Shi, Yang Fu & Yingjie Zhang. (2022) In situ injectable hydrogel-loaded drugs induce anti-tumor immune responses in melanoma immunochemotherapy. Materials Today Bio 14, pages 100238.
Crossref
Jeongrae Kim, Yongwhan Choi, Suah Yang, Jaewan Lee, Jiwoong Choi, Yujeong Moon, Jinseong Kim, Nayeon Shim, Hanhee Cho, Man Kyu Shim, Sangmin Jeon, Dong-Kwon Lim, Hong Yeol Yoon & Kwangmeyung Kim. (2022) Sustained and Long-Term Release of Doxorubicin from PLGA Nanoparticles for Eliciting Anti-Tumor Immune Responses. Pharmaceutics 14:3, pages 474.
Crossref
Sajal Sen, Miae Won, Matthew S. Levine, Yuvin Noh, Adam C. Sedgwick, Jong Seung Kim, Jonathan L. Sessler & Jonathan F. Arambula. (2022) Metal-based anticancer agents as immunogenic cell death inducers: the past, present, and future. Chemical Society Reviews 51:4, pages 1212-1233.
Crossref
Benedikt Kolbrink, Theresa Riebeling, Nikolas K. Teiwes, Claudia Steinem, Hubert Kalbacher, Ulrich Kunzendorf & Stefan Krautwald. (2022) TAT–RHIM: a more complex issue than expected. Biochemical Journal 479:3, pages 259-272.
Crossref
Cherylette Anne Alexander & Yi Yan Yang. (2022) Harnessing the combined potential of cancer immunotherapy and nanomedicine: A new paradigm in cancer treatment. Nanomedicine: Nanotechnology, Biology and Medicine 40, pages 102492.
Crossref
Noel E. Donlon, Maria Davern, Andrew D. Sheppard, Fiona O’Connell, Margaret R. Dunne, Conall Hayes, Eimear Mylod, Sinead Ramjit, Hugo Temperley, Michael Mac Lean, Gillian Cotter, Anshul Bhardwaj, Christine Butler, Melissa J. Conroy, Jacintha O’Sullivan, Narayanasamy Ravi, Claire L. Donohoe, John V. Reynolds & Joanne Lysaght. (2022) The Impact of Esophageal Oncological Surgery on Perioperative Immune Function; Implications for Adjuvant Immune Checkpoint Inhibition. Frontiers in Immunology 13.
Crossref
Davide Ciardiello, Brigida Anna Maiorano, Paola Parente, Maria Grazia Rodriquenz, Tiziana Pia Latiano, Cinzia Chiarazzo, Valerio Pazienza, Luigi Pio Guerrera, Brunella Amoruso, Nicola Normanno, Giulia Martini, Fortunato Ciardiello, Erika Martinelli & Evaristo Maiello. (2022) Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives. International Journal of Molecular Sciences 23:2, pages 820.
Crossref
Zhicheng Wang, Chao Sun, Haijun Wu, Jizhen Xie, Tong Zhang, Yumin Li, Xuelian Xu, Peilin Wang & Cheng Wang. (2022) Cascade targeting codelivery of ingenol-3-angelate and doxorubicin for enhancing cancer chemoimmunotherapy through synergistic effects in prostate cancer. Materials Today Bio 13, pages 100189.
Crossref
Catherine Passirani, Anne Vessières, Giuseppe La Regina, Wolfgang Link & Romano Silvestri. (2022) Modulating undruggable targets to overcome cancer therapy resistance. Drug Resistance Updates 60, pages 100788.
Crossref
Sabrina Forveille, Allan Sauvat, Shuai Zhang, Liwei Zhao, Guido Kroemer & Oliver Kepp. 2022. Radiation Oncology and Radiotherapy Part A. Radiation Oncology and Radiotherapy Part A 135 143 .
Giulia Cerrato, Juliette Humeau, Allan Sauvat, Oliver Kepp & Guido Kroemer. 2022. Radiation Oncology and Radiotherapy Part A. Radiation Oncology and Radiotherapy Part A 67 82 .
Hae Lin Jang & Shiladitya Sengupta. 2022. Cancer Immunology and Immunotherapy. Cancer Immunology and Immunotherapy 439 461 .
Alexia Nathália Brígido Assef, Bianca Barros da Costa, Thamyris Almeida Moreira, Luana David do Carmo, Tamiris de Fátima Goebel de Souza, Nylane Maria Nunes Alencar, Ana Paula Negreiros Nunes Alves, Leonardo Paes Cinelli & Diego Veras Wilke. (2021) Antitumor and immunostimulating sulfated polysaccharides from brown algae Dictyota caribaea. Carbohydrate Polymer Technologies and Applications 2, pages 100142.
Crossref
Rui He, Yefang Lao, Wenyan Yu, Xiaohui Zhang, Min Jiang & Chunrong Zhu. (2021) Progress in the Application of Immune Checkpoint Inhibitor-Based Immunotherapy for Targeting Different Types of Colorectal Cancer. Frontiers in Oncology 11.
Crossref
Jie Wang, Ning Liu, Hongfei Jiang, Qian Li & Dongming Xing. (2021) Reactive Oxygen Species in Anticancer Immunity: A Double-Edged Sword. Frontiers in Bioengineering and Biotechnology 9.
Crossref
Victoria Smith Arnesen, Andrea Gras Navarro & Martha Chekenya. (2021) Challenges and Prospects for Designer T and NK Cells in Glioblastoma Immunotherapy. Cancers 13:19, pages 4986.
Crossref
Ornella Franzese, Francesco Torino, Elisa Giannetti, Giorgia Cioccoloni, Angelo Aquino, Isabella Faraoni, Maria Pia Fuggetta, Liana De Vecchis, Anna Giuliani, Bernd Kaina & Enzo Bonmassar. (2021) Abscopal Effect and Drug-Induced Xenogenization: A Strategic Alliance in Cancer Treatment?. International Journal of Molecular Sciences 22:19, pages 10672.
Crossref
Asvelt J. Nduwumwami, Jeremy A. Hengst & Jong K. Yun. (2021) Sphingosine Kinase Inhibition Enhances Dimerization of Calreticulin at the Cell Surface in Mitoxantrone-Induced Immunogenic Cell Death. Journal of Pharmacology and Experimental Therapeutics 378:3, pages 300-310.
Crossref
Irina Alekseenko, Alexey Kuzmich, Liya Kondratyeva, Sofia Kondratieva, Victor Pleshkan & Eugene Sverdlov. (2021) Step-by-Step Immune Activation for Suicide Gene Therapy Reinforcement. International Journal of Molecular Sciences 22:17, pages 9376.
Crossref
Kellsye P. Fabian, Benjamin Wolfson & James W. Hodge. (2021) From Immunogenic Cell Death to Immunogenic Modulation: Select Chemotherapy Regimens Induce a Spectrum of Immune-Enhancing Activities in the Tumor Microenvironment. Frontiers in Oncology 11.
Crossref
Mengqin Zhu, Mengdie Yang, Jiajia Zhang, Yuzhen Yin, Xin Fan, Yu Zhang, Shanshan Qin, Han Zhang & Fei Yu. (2021) Immunogenic Cell Death Induction by Ionizing Radiation. Frontiers in Immunology 12.
Crossref
Mercedes Beatriz Fuertes, Carolina Inés Domaica & Norberto Walter Zwirner. (2021) Leveraging NKG2D Ligands in Immuno-Oncology. Frontiers in Immunology 12.
Crossref
Fan Zhang, Fangman Chen, Chao Yang, Lei Wang, Hanze Hu, Xuezhao Li, Xiao Zheng, Zheng Wang, Zhimin Chang, Tianyu Li, Li Li, Mingfeng Ge, Jinzhi Du, Wen Sun, Wen‐fei Dong & Dan Shao. (2021) Coordination and Redox Dual‐Responsive Mesoporous Organosilica Nanoparticles Amplify Immunogenic Cell Death for Cancer Chemoimmunotherapy. Small 17:26.
Crossref
Ahmed Salah, Hao Wang, Yanqin Li, Meng Ji, Wen-Bin Ou, Nianmin Qi & Yuehong Wu. (2021) Insights Into Dendritic Cells in Cancer Immunotherapy: From Bench to Clinical Applications. Frontiers in Cell and Developmental Biology 9.
Crossref
Jonathan Pol. (2021) Valeur pronostique et prédictive de l’Immunoscore dans les cancers du côlon et de la vessie. Hegel N° 2:2, pages 113-118.
Crossref
Pottayil G. Sasikumar, Naremaddepalli S. Sudarshan, Srinivas Adurthi, Raghuveer K. Ramachandra, Dodderi S. Samiulla, Anirudha Lakshminarasimhan, Anuradha Ramanathan, Talapaneni Chandrasekhar, Amit A. Dhudashiya, Sumalatha R. Talapati, Nagesh Gowda, Sreenivasulareddy Palakolanu, Jiju Mani, Bandi Srinivasrao, David Joseph, Nigam Kumar, Rashmi Nair, Hanudatta S. Atreya, Nagaraj Gowda & Murali Ramachandra. (2021) PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy. Communications Biology 4:1.
Crossref
Ángela-Patricia Hernández, Pablo Juanes-Velasco, Alicia Landeira-Viñuela, Halin Bareke, Enrique Montalvillo, Rafael Góngora & Manuel Fuentes. (2021) Restoring the Immunity in the Tumor Microenvironment: Insights into Immunogenic Cell Death in Onco-Therapies. Cancers 13:11, pages 2821.
Crossref
Natalia Anger‑góra, Katarzyna Węgierek‑Ciura, Agnieszka Szczygieł, Jagoda Mierzejewska, Elżbieta Pajtasz‑Piasecka & Joanna Rossowska. (2021) Treatment with lentiviral vectors encoding shRNA against interleukin 10 modulates the immunosuppressive activity of murine colon carcinoma‑associated myeloid‑derived suppressor cells. Oncology Letters 22:2.
Crossref
Diego Salas-Benito, José L. Pérez-Gracia, Mariano Ponz-Sarvisé, María E. Rodriguez-Ruiz, Iván Martínez-Forero, Eduardo Castañón, José M. López-Picazo, Miguel F. Sanmamed & Ignacio Melero. (2021) Paradigms on Immunotherapy Combinations with Chemotherapy. Cancer Discovery 11:6, pages 1353-1367.
Crossref
Benedetta Pellegrino, Chiara Tommasi, Olga Elisabetta Cursio, Antonino Musolino, Edoardo Migliori, Pushpamali De Silva, Thilini Hemali Senevirathne, Marina Schena, Mario Scartozzi, Daniele Farci, Karen Willard-Gallo & Cinzia Solinas. (2021) A review of immune checkpoint blockade in breast cancer. Seminars in Oncology 48:3, pages 208-225.
Crossref
Isaure Vanmeerbeek, Daniel M. Borras, Jenny Sprooten, Oliver Bechter, Sabine Tejpar & Abhishek D. Garg. (2021) Early memory differentiation and cell death resistance in T cells predicts melanoma response to sequential anti-CTLA4 and anti-PD1 immunotherapy. Genes & Immunity 22:2, pages 108-119.
Crossref
Ming-Zhu Jin & Xi-Peng Wang. (2021) Immunogenic Cell Death-Based Cancer Vaccines. Frontiers in Immunology 12.
Crossref
Lorenzo Galluzzi & Abhishek D. Garg. (2021) Immunology of Cell Death in Cancer Immunotherapy. Cells 10:5, pages 1208.
Crossref
Xiaodan Jiao, Lihong Sun, Wei Zhang, Junjie Ren, Lei Zhang, Yang Cao, Zhigang Xu, Yuejun Kang & Peng Xue. (2021) Engineering oxygen-deficient ZrO2-x nanoplatform as therapy-activated “immunogenic cell death (ICD)” inducer to synergize photothermal-augmented sonodynamic tumor elimination in NIR-II biological window. Biomaterials 272, pages 120787.
Crossref
Yan-Qi Li, Zhi Zheng, Quan-Xing Liu, Xiao Lu, Dong Zhou, Jiao Zhang, Hong Zheng & Ji-Gang Dai. (2021) Repositioning of Antiparasitic Drugs for Tumor Treatment. Frontiers in Oncology 11.
Crossref
Tianqi Wang, Yusuke Suita, Saradha Miriyala, Jordan Dean, Nikos Tapinos & Jie Shen. (2021) Advances in Lipid-Based Nanoparticles for Cancer Chemoimmunotherapy. Pharmaceutics 13:4, pages 520.
Crossref
Cinzia Solinas, Debora Fumagalli & Maria Vittoria Dieci. (2021) Immune Checkpoint Blockade in HER2-Positive Breast Cancer: What Role in Early Disease Setting?. Cancers 13:7, pages 1655.
Crossref
Chit Tam, Shitao Rao, Mary Miu Yee Waye, Tzi Bun Ng & Chi Chiu Wang. (2021) Autophagy signals orchestrate chemoresistance of gynecological cancers. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1875:2, pages 188525.
Crossref
Jun Li, Yuan Fang, Yufan Zhang, Huaimin Wang, Zhimou Yang & Dan Ding. (2021) Supramolecular Self‐Assembly‐Facilitated Aggregation of Tumor‐Specific Transmembrane Receptors for Signaling Activation and Converting Immunologically Cold to Hot Tumors. Advanced Materials 33:16.
Crossref
Xue Wang, Xiaomin Niu, Na An, Yile Sun & Zhiwei Chen. (2021) Comparative Efficacy and Safety of Immunotherapy Alone and in Combination With Chemotherapy for Advanced Non-small Cell Lung Cancer. Frontiers in Oncology 11.
Crossref
Minsu Kwon, Hanul Jung, Gi-Hoon Nam & In-San Kim. (2021) The right Timing, right combination, right sequence, and right delivery for Cancer immunotherapy. Journal of Controlled Release 331, pages 321-334.
Crossref
Carlos del Fresno & David Sancho. (2021) Myeloid cells in sensing of tissue damage. Current Opinion in Immunology 68, pages 34-40.
Crossref
Reza Mehdizadeh, Seyed Peyman Shariatpanahi, Bahram Goliaei, Sanam Peyvandi & Curzio Rüegg. (2021) Dormant Tumor Cell Vaccination: A Mathematical Model of Immunological Dormancy in Triple-Negative Breast Cancer. Cancers 13:2, pages 245.
Crossref
Marc Armengol, Juliana Carvalho Santos, Miranda Fernández-Serrano, Núria Profitós-Pelejà, Marcelo Lima Ribeiro & Gaël Roué. (2021) Immune-Checkpoint Inhibitors in B-Cell Lymphoma. Cancers 13:2, pages 214.
Crossref
Alexandra Leary, David Tan & Jonathan Ledermann. (2021) Immune checkpoint inhibitors in ovarian cancer: where do we stand?. Therapeutic Advances in Medical Oncology 13, pages 175883592110398.
Crossref
Patrick Greve, Friederike A G Meyer-Wentrup, Victor Peperzak & Marianne Boes. (2021) Upcoming immunotherapeutic combinations for B-cell lymphoma. Immunotherapy Advances 1:1.
Crossref
Milada Zemanova, Marketa Cernovska, Libor Havel, Tomas Bartek, Sarka Lukesova, Jitka Jakesova, Jaroslav Vanasek, Pavel Reiterer, Juraj Kultan, Igor Andrasina, Lenka Siskova, Leona Koubkova, Jana Skrickova, Frantisek Salajka, Milos Pesek, Petr Klepetko, Juraj Beniak, Harald Fricke, Pavla Kadlecova, Roman P. Korolkiewicz, Marek Hraska, Jirina Bartunkova & Radek Spisek. (2021) Autologous dendritic cell-based immunotherapy (DCVAC/LuCa) and carboplatin/paclitaxel in advanced non-small cell lung cancer: A randomized, open-label, phase I/II trial. Cancer Treatment and Research Communications 28, pages 100427.
Crossref
Licia Rivoltini, Agata Cova & Paola Squarcina. 2021. New Therapies in Advanced Cutaneous Malignancies. New Therapies in Advanced Cutaneous Malignancies 99 128 .
Hung‐Wei Cheng, Hsin‐Yi Tsao, Chih‐Sheng Chiang & San‐Yuan Chen. (2020) Advances in Magnetic Nanoparticle‐Mediated Cancer Immune‐Theranostics. Advanced Healthcare Materials 10:1.
Crossref
Binbin Cheng, Wei Wang, Xiaoge Niu, Yichang Ren, Ting Liu, Hao Cao, Shuanghu Wang, Yingfeng Tu, Jingxuan Chen, Shuwen Liu, Xuchao Yang & Jianjun Chen. (2020) Discovery of Novel and Highly Potent Resorcinol Dibenzyl Ether-Based PD-1/PD-L1 Inhibitors with Improved Drug-like and Pharmacokinetic Properties for Cancer Treatment. Journal of Medicinal Chemistry 63:24, pages 15946-15959.
Crossref
K. Hayashi, F. Nikolos, Y. C. Lee, A. Jain, E. Tsouko, H. Gao, A. Kasabyan, H. E. Leung, A. Osipov, S. Y. Jung, A. V. Kurtova & K. S. Chan. (2020) Tipping the immunostimulatory and inhibitory DAMP balance to harness immunogenic cell death. Nature Communications 11:1.
Crossref
Lorenzo Galluzzi, Juliette Humeau, Aitziber Buqué, Laurence Zitvogel & Guido Kroemer. (2020) Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nature Reviews Clinical Oncology 17:12, pages 725-741.
Crossref
Changlin Li, Hui Sun, Wei Wei, Qiuzi Liu, Yinglei Wang, Ying Zhang, Fuming Lian, Fangchao Liu, Chenchen Li, Kaicheng Ying, Hang Huo, Zhi Qi & Benyi Li. (2020) Mitoxantrone triggers immunogenic prostate cancer cell death via p53-dependent PERK expression. Cellular Oncology 43:6, pages 1099-1116.
Crossref
Yimou Gong, Muchao Chen, Yanjun Tan, Jingjing Shen, Qiutong Jin, Wutong Deng, Jian Sun, Chao Wang, Zhuang Liu & Qian Chen. (2020) Injectable Reactive Oxygen Species-Responsive SN38 Prodrug Scaffold with Checkpoint Inhibitors for Combined Chemoimmunotherapy. ACS Applied Materials & Interfaces 12:45, pages 50248-50259.
Crossref
Constantin N. Baxevanis, Sotirios P. Fortis, Alexandros Ardavanis & Sonia A. Perez. (2020) Exploring Essential Issues for Improving Therapeutic Cancer Vaccine Trial Design. Cancers 12:10, pages 2908.
Crossref
Cristina Belgiovine, Elisabeth Digifico, Clément Anfray, Aldo Ummarino & Fernando Torres Andón. (2020) Targeting Tumor-Associated Macrophages in Anti-Cancer Therapies: Convincing the Traitors to Do the Right Thing. Journal of Clinical Medicine 9:10, pages 3226.
Crossref
Varsha Gadiyar, Kevin C. Lahey, David Calianese, Connor Devoe, Dhriti Mehta, Kristy Bono, Samuel Desind, Viralkumar Davra & Raymond B. Birge. (2020) Cell Death in the Tumor Microenvironment: Implications for Cancer Immunotherapy. Cells 9:10, pages 2207.
Crossref
Guillaume Sicard, Frédéric Fina, Raphaelle Fanciullino, Fabrice Barlesi & Joseph Ciccolini. (2020) Like a Rolling Stone: Sting-Cgas Pathway and Cell-Free DNA as Biomarkers for Combinatorial Immunotherapy. Pharmaceutics 12:8, pages 758.
Crossref
Jenny Sprooten, Pieter De Wijngaert, Isaure Vanmeerbeek, Shaun Martin, Peter Vangheluwe, Susan Schlenner, Dmitri V. Krysko, Jan B. Parys, Geert Bultynck, Peter Vandenabeele & Abhishek D. Garg. (2020) Necroptosis in Immuno-Oncology and Cancer Immunotherapy. Cells 9:8, pages 1823.
Crossref
Roberto Moretto, Salvatore Corallo, Antonino Belfiore, Daniele Rossini, Alessandra Boccaccino, Sara Lonardi, Giovanni Centonze, Federica Morano, Marco Maria Germani, Fotios Loupakis, Luca Morelli, Lucio Urbani, Silvia Brich, Federica Marmorino, Michele Prisciandaro, Giuseppe Aprile, Matteo Fassan, Umberto Cillo, Laura Cattaneo, Gabriella Fontanini, Filippo De Braud, Alfredo Falcone, Massimo Milione, Filippo Pietrantonio & Chiara Cremolini. (2020) Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials. European Journal of Cancer 135, pages 78-88.
Crossref
Aline Houessinon, Aurélie Moreira, Jérèmie Bettoni, Marine Schoonaker, Chloé Sauzay, Antoine Galmiche, Alexandre Coutte, Aurélie Biet, Claude Krzisch & Bruno Chauffert. (2020) Resensitization to Nivolumab after Intratumoral Chemotherapy in Recurrent Head and Neck Squamous Cell Cancer: A Report of 2 Cases. Case Reports in Oncology 13:2, pages 835-842.
Crossref
Jofer Andree Zamame Ramirez, Graziela Gorete Romagnoli, Bianca Francisco Falasco, Carolina Mendonça Gorgulho, Carla Sanzochi Fogolin, Daniela Carvalho dos Santos, João Pessoa Araújo Junior, Michael Thomas Lotze, Rodrigo Portes Ureshino & Ramon Kaneno. (2020) Blocking drug-induced autophagy with chloroquine in HCT-116 colon cancer cells enhances DC maturation and T cell responses induced by tumor cell lysate. International Immunopharmacology 84, pages 106495.
Crossref
Pierpaolo Ginefra, Girieca Lorusso & Nicola Vannini. (2020) Innate Immune Cells and Their Contribution to T-Cell-Based Immunotherapy. International Journal of Molecular Sciences 21:12, pages 4441.
Crossref
Tal Flieswasser, Jinthe Van Loenhout, Laurie Freire Boullosa, Astrid Van den Eynde, Jorrit De Waele, Jonas Van Audenaerde, Filip Lardon, Evelien Smits, Patrick Pauwels & Julie Jacobs. (2020) Clinically Relevant Chemotherapeutics Have the Ability to Induce Immunogenic Cell Death in Non-Small Cell Lung Cancer. Cells 9:6, pages 1474.
Crossref
Antonio Di Grazia, Federica Laudisi, Davide Di Fusco, Eleonora Franzè, Angela Ortenzi, Ivan Monteleone, Giovanni Monteleone & Carmine Stolfi. (2020) Rafoxanide Induces Immunogenic Death of Colorectal Cancer Cells. Cancers 12:5, pages 1314.
Crossref
Qianqian Liu, Yanhong Sun, Xiaoyan Yin, Jun Li, Jun Xie, Meng Xie, Ke Wang, Shidi Wu, Yuce Li, Mubashir Hussain, Biling Jiang, Yijing Liu, Changzheng Huang, Juan Tao & Jintao Zhu. (2020) Hyaluronidase-Functionalized Silica Nanocarrier for Enhanced Chemo-Immunotherapy through Inducing Immunogenic Cell Death. ACS Applied Bio Materials 3:5, pages 3378-3389.
Crossref
Rachid Bouzid, Maikel Peppelenbosch & Sonja I. Buschow. (2020) Opportunities for Conventional and In Situ Cancer Vaccine Strategies and Combination with Immunotherapy for Gastrointestinal Cancers, A Review. Cancers 12:5, pages 1121.
Crossref
Joanna Kopecka, Martina Godel, Silvia Dei, Roberta Giampietro, Dimas Carolina Belisario, Muhlis Akman, Marialessandra Contino, Elisabetta Teodori & Chiara Riganti. (2020) Insights into P-Glycoprotein Inhibitors: New Inducers of Immunogenic Cell Death. Cells 9:4, pages 1033.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.